Kicking the Habit: The Opioid Crisis and America’s Addiction to Prohibition

Law enforcement’s recent push for punishment might succeed in limiting opioid prescriptions but only at the cost of driving drug‐​dependent individuals into more dangerous criminal markets and toward adulterated street heroin and fentanyl. For individuals addicted to opioids or suffering from chronic pain, a war on drugs has never been a prescription for improving wellness.

June 29, 2020 • Policy Analysis No. 894
By Josh Bowers and Daniel Abrahamson

There is no single cause of America’s opioid crisis, but overprescription of opioids has undoubtedly contributed. The federal government has responded predictably, criminally prosecuting doctors who prescribe opioids to the drug dependent. The approach may seem sensible, but it is as wrongheaded as our century‐​old drug war. Law enforcement’s recent push for punishment might succeed in limiting opioid prescriptions but only at the cost of driving drug‐​dependent individuals into more dangerous criminal markets and toward adulterated street heroin and fentanyl. For individuals addicted to opioids or suffering from chronic pain, a war on drugs has never been a prescription for improving wellness. This dominant abstinence‐​based policy model is grounded in the logic of prohibition, and it depends not upon healing but upon shame, isolation, prosecution, and penalty. The better model is “harm reduction,” grounded in connection and care, reason and rights, and human dignity and worth.

International and historical public health efforts have demonstrated that one of the best ways to confront epidemic drug use is addiction maintenance—that is, establishing medically supervised clinics to provide pharmaceutical‐​grade narcotics (often free of charge) in amounts calibrated to maintain the social and physical well‐​being of the drug dependent. In this policy analysis, we survey these international and historical efforts. We look to our own past to examine the roots of the modern American drug war and describe contemporary reforms both within and beyond the opioid crisis. We explain how meaningful change is likeliest to occur: from the ground up, as a product of underground experimentation initiated by and within the most‐​affected communities. Finally, we offer our own public health prescription: a set of pragmatic harm‐​reduction responses to prohibition and its counterproductive and often deadly effects.


For a century, the United States has fought a war on drugs.1 Some strategies have changed over time, of course. The state has diverted manpower from opium to other substances, including heroin, marijuana, hallucinogens, powder and crack cocaine, and prescription and nonprescription opioids. Likewise, police, prosecutors, and politicians have supplemented conventional statutory approaches, such as the Harrison Narcotics Act, with more powerful policies, including the Controlled Substances Act and other state‐​law corollaries.2 Other strategies have remained constant. For instance, law enforcement has kept its sights trained throughout the drug war on low‐​income and minority neighborhoods.

More to the point, the goal of the drug war—punitive prohibition—has never shifted. With the exceptions of alcohol, tobacco, and, to a narrow extent, marijuana, recreational drugs are still forbidden, and users are still prosecuted. The state has consistently prohibited much more, even prosecuting the activists and medical professionals who would help problematic drug users through unconventional but promising means. It has defunded studies searching for innovative approaches to solve the problems arising from drug use and abuse, and it has undermined local reform efforts. The state’s objective is a drug‐​free society—full stop.

An entire study could be devoted to unpacking the reasons for the drug war’s obsession with prohibition. It is enough, however, to flag three principal influences. First, the drug war’s preoccupation with prohibition lies partially in America’s history and worldview.3 Second, and to a greater degree, punitive prohibition is rooted in racism. Third, and more subtle, the logic of punitive prohibition follows a fixation with rules. Prohibition is what happens when public policy is left to be shaped from the top down. The war on drugs exposes a particular drawback of law, legal institutions, and the legal turn of mind: all have a tendency toward rigid rules, intimidation, and aversion to risk and experimentation.4

While some legal regimes and bureaucratic frameworks have great value, many tend to fall prey to limited perspectives that not only make for misguided public policy but also complicate course correction. Simple answers are preferred to the pursuit of nuanced solutions. On this reasoning, prohibition takes on a certain elegance, captured by the directive, “Just Say No.”5 One might dismiss this as no more than an anodyne public service message. But those three words succinctly describe much more: a century of a state‐​sponsored war on drugs that has proven to be a public health failure.

Yet now, in the face of a brutal opioid crisis, there is a modicum of energy for genuine drug policy reform—for a shift from the prevailing just‐​say‐​no mentality. The shift is welcome, of course. Still, it is hard to get too excited about a newfound enthusiasm that is, in itself, seemingly grounded in racial bias. White America has opened its eyes to the evils of the drug war at the very moment that the opioid epidemic has begun to plague rural and predominantly white communities.6 We are witnessing an example of interest convergence theory in action, which posits that white America will only see fit to help black America if white Americans are forced to face the same challenges as black Americans.7 Simply put, there are limits to a polity’s moral imagination when the problem exists “over there” only.

We would rather see reform grounded in a genuine commitment to civil, constitutional, and human rights—in a commitment to the liberty, equality, dignity, and interests of all drug users and their circles of social support. All the same, we are pragmatic drug policy reformers. And, because lives do in fact hang in the balance, we’ll take what we can get—including any opportunity to shift the narrative, however slightly, from that of a criminal justice menace to a public health crisis.

In this policy analysis, we address the historical and contemporary approaches to addiction treatment and policy. First, we recall a time, before our centurylong war on drugs, when America responded to an opioid epidemic not with prohibition but with an intervention known as addiction maintenance—that is, providing drugs in amounts calibrated to maintain the well‐​being of dependent persons. We examine what changed and how we came to abandon that harm‐​reduction model.8 Next, we explore contemporary international efforts to return to an old‐​style, harm‐​reduction approach. In the process, we explore some of the advantages of addiction maintenance in its modern form. Then we discuss how, when, and why addiction maintenance works and evaluate what stands in the way of addiction maintenance. Finally, we survey a host of domestic reform efforts and provide a framework for understanding when, how, and to what extent these endeavors have succeeded.

As these reform efforts reveal, addiction maintenance is only one front in harm reduction. Indeed, additional reforms necessarily must precede addiction maintenance because the practice is appropriate only after the failure of other much‐​needed therapeutic interventions—such as medication‐​assisted treatment with methadone, buprenorphine, or suboxone, none of which are uniformly available at present. We conclude with a six‐​point plan, designed to address the current opioid crisis in a manner that moves away from prohibition and toward harm reduction.

Early Addiction Maintenance Efforts

Throughout the 19th century, drugs remained mostly unregulated.9 Users purchased products through mail‐​order catalogs and at local pharmacies.10 Sears, Roebuck and Company sold syringes with doses of injectable cocaine for one or two dollars.11 Opiates were packaged into serums with delightfully alliterative names, like “Mrs. Winslow’s Soothing Syrup.”12 And, critically, this legal market was substantially safer than the modern‐​day criminal market:

Before the ban, almost all opiate users would buy a mild form of the drug at their corner store for a small price. A few did become addicts, and that meant their lives were depleted, in the same way that an alcoholic’s life is depleted today… . But virtually none of them committed crimes to get their drug, or became wildly out of control, or lost their jobs. Then the legal routes to the drug were cut off—and all the problems we associate with drug addiction began: criminality, prostitution, violence.13

Medical professionals of the era considered opioid abuse a public health problem.14 The idea of a drug war would likely have seemed foreign to them.15 To the contrary, doctors regarded persons suffering from drug addiction as patients deserving of treatment.16 Even for the profoundly dependent, the medical profession provided a form of palliative care—often termed addiction maintenance—by which cravings were treated by access to the craved substance.17

By the turn of the century, the push for prohibition had begun—in part as a means to control minority communities. Politicians, pastors, and the press drew specious links between drug abuse and the exploitation of white women.18 These early drug warriors pushed for aggressive state responses, playing on racial stereotypes.19 African Americans were singled out for especially harsh treatment. Unsubstantiated claims linked black drug abuse to “many of the horrible crimes committed in the Southern States,” thus providing another convenient excuse for all varieties of Jim Crow persecution and oppression, including continued disenfranchisement.20 Notably, Harry Anslinger—the first commissioner of the Federal Bureau of Narcotics—was an unapologetic bigot who waged a ruthless (and almost bizarrely personal and obsessive) campaign against African American jazz singer and drug user Billie Holiday.21

Then, as now, whites used drugs at rates comparable to—and perhaps even higher than—other populations.22 Indeed, historian David Courtwright concludes that “southern whites [of the era] had the highest addiction rate of any regional racial group in the country, and perhaps one of the highest in the world.”23 But, among more‐​privileged populations, it seems that drug abuse was still considered no worse than an unfortunate but tolerable vice.24 In other words, attitudes about recreational drugs were shaped by caste and class—by the desire to prevent the “wrong” type from associating with the “right” type. Unsurprisingly, then, the first shots of the drug war were, like most shots since, targeted strikes against poorer and darker communities.25

What did early regulation look like? In 1914, Congress passed the Harrison Narcotics Tax Act, which taxed, but did not wholly prohibit, the production and distribution of cocaine and opioids.26 In this way, doctors could still prescribe narcotics, and many continued to do so to treat dependence. In fact, several municipalities ran public addiction maintenance clinics, including opioid clinics in New York City, Los Angeles, New Orleans, Shreveport, Atlanta, New Haven, Albany, and Jacksonville.27 These dispensaries operated aboveground, granting prescriptions for hard drugs to users. Health officials not only treated but also tracked patients.28 Participants were required to register with the state, which minimized the risk of diversion of the drugs into criminal markets and provided a data source to measure success empirically—even though such studies were apparently relatively uncommon at the time.29

It seems that the efforts were largely successful. If nothing else, they initially enjoyed widespread support from city councils, boards of health, and even local law enforcement.30 According to one city official in Los Angeles, the city’s maintenance clinic “did more good … in one day than all the prosecutions in one month.“31 But the legal landscape was shifting. “Law enforcement officials soon began to move to curtail the medical profession’s freedom to prescribe narcotics in the treatment of addicts.”32 Initially, law enforcement focused on the so‐​called script doctors who liberally dispensed opioids to patients. Federal prosecutors argued that addiction maintenance failed to qualify under the Harrison Act’s allowance for good faith prescriptions in the course of professional practice.33 And the Supreme Court would come to agree. First, in Webb v. United States, the court held that a doctor was prohibited from prescribing to a habitual user a dose of morphine if the doctor’s intention was not to cure the habit but to keep the patient “comfortable by maintaining his customary use.”34 Subsequently, in Jin Fuey Moy v. United States, the court reaffirmed this position, observing that a prescription could not “cater to the appetite … of one addicted to the use of the drug.”35 Finally, in United States v. Behrman, the court held that a violation of the Harrison Act did not turn on a doctor’s subjective motivation,36 meaning that “prescribing drugs for an addict was a crime regardless of the physician’s intent in the matter.”37 Somewhat surprisingly, however, in Linder v. United States, the court endorsed a different approach:

[Addicts] . . . are diseased, and proper subjects for such treatment, and we cannot possibly conclude that a physician acted improperly or unwisely or for other than medical purposes solely because he has dispensed to one of them, in the ordinary course and in good faith . . . morphine or cocaine for relief of conditions incident to addiction.38

But Linder would prove to be sui generis—an exception to the dominant rule, applied to a case where the doctor had prescribed only a relatively small dose.39 The Harrison Act had set the stage for punitive prohibition. And, with the passage of the Eighteenth Amendment, the logic of prohibition became a constitutional mandate, shifting both legal and cultural norms.40 Enforcement of the Harrison Act “stigmatized medication‐​assisted treatment as well as the patients who received such care.”41 In short order, the practice of addiction maintenance disappeared.42 By 1925, the last clinic had closed.43

With the repeal of the Eighteenth Amendment in 1933, there was, perhaps, some hope that the state might soften its approach to prohibition writ large.44 To the contrary, federal officials, now relieved of alcohol‐​interdiction duties, were free to devote even more time and criminal justice energy to narcotics.45

The government had its reasons, of course, to worry about unscrupulous physicians who indiscriminately dispensed opioids and other drugs.46 There is a legitimate concern about the diversion of prescription drugs into criminal markets.47 And the line is fine between treating and creating drug dependency. Thus the Harrison Act replaced the physician’s tools with the threats of the criminal justice system. “The unfortunate consequence of this policy was to drive from the field of treatment not only the unethical ‘script doctor’ but the legitimate doctor as well.”48

International Public Health Efforts

Beyond our borders, several cities and countries have, for some time, successfully provided free, uncontaminated, comparatively safe narcotics to persons addicted to controlled substances.49 Among those closest to home, Vancouver has witnessed a grassroots campaign undertaken by drug users—the Vancouver Area Network of Drug Users (VANDU)—to support and care for each other.50 VANDU initially established an underground, supervised injection facility: a sterile, medically staffed environment to which recreational users could bring drugs to consume in relative safety.51 And, as VANDU’s successes became apparent, it took its efforts mainstream.52 It pressured the municipality to declare a public health emergency and won the support of the city’s conservative mayor, Philip Owen.53 Then Vancouver opened Insite, the first licit drug‐​consumption safe site in North America.54 Drug users who brought their drugs to Insite were made safe in three ways: they were insulated from arrest and prosecution, they were given sterile injection equipment and other drug‐​use paraphernalia, and they were supervised by medical professionals prepared to administer naloxone and oxygen as needed to reverse overdoses.55

The results were transformative. To date, Insite claims to have reversed nearly 5,000 overdoses without suffering a single overdose death.56 More than that, clean needles have kept injectable‐​drug users from transmitting communicable diseases, such as HIV and hepatitis.57 And, as participants have moved their habits—and needles—indoors, quality of life in Vancouver’s formerly derelict Downtown Eastside has improved dramatically.58 Many heavy drug users have reduced or even ceased their drug use and have secured stable employment and housing.59 Notably, between 1996 and 2006, life expectancy in the Downtown Eastside rose by several years.60 These results are in keeping with recent research tracing the roots of addiction.61 The current phrase is, “The opposite of addiction is connection,” and by normalizing but still discouraging drug use, these international experiments have served to reconnect dependent drug‐​users with their communities.62

But, ultimately, the safe site was not enough to effectively serve the needs of drug‐​affected Vancouver communities. Thus the city opened the Providence Crosstown Clinic, which operates on a genuine addiction maintenance model.63 At Crosstown, staff provide addicts with pharmaceutical‐​grade heroin in a supervised setting with care sometimes paid for by Health Canada (the country’s national public health care provider).64 The program reaches the very individuals that criminal legal systems label recidivists.65 Indeed, many participants have previously cycled through Canadian jails and prisons—to no avail.66 Crosstown makes heroin available to patients for whom all other interventions have failed, including even medication‐​assisted therapy with methadone, buprenorphine, or suboxone.67 Out of options, Vancouver took the only viable step left: the city turned to free heroin, turning run‐​of‐​the‐​mill repeat offenders into patients.68

The aim is palliative care.69 First, harm is reduced to the opioid‐​dependent person by providing clean needles in a clinical setting and drugs of predictable quality, unadulterated by more toxic substances such as fentanyl.70 Second, harm is reduced to the public by minimizing the incentives of drug seekers to commit property and violent crimes to feed drug habits.71 The operating philosophy is not American‐​style prohibition or use reduction.72 To the contrary, there is little expectation that habitual users will even taper their usage in the near future.73 The idea is to transform the heavy drug user into a functional and socially productive individual who need not spend every waking moment evading law enforcement to furtively score and use illicit substances of unknown purity, potency, and provenance.74 To that end, the clinic also offers other supportive services, such as social workers on staff and job and housing programs, all designed to help participants maintain social connections and construct lives of meaning, even as participants remain drug dependent.75 But it should be noted that opportunities are likewise available to participants to transition to more conventional treatment, including abstinence‐​based programs, meaning that participants may ultimately reduce use, although that is not the core objective.

Vancouver’s efforts were built upon those of mainly European countries that had previously fashioned innovative harm reduction interventions, including the establishment of addiction maintenance programs. For instance, dating back to the 1980s, the city of Liverpool, England, experimented with prescription “heroin reefers”—cigarettes soaked in heroin.76 Although few data were developed or kept, a police study showed that criminal convictions for drug‐​addicted persons dropped from 6.88 convictions per individual in the 18 months prior to enrollment to only 0.44 convictions in the 18 months thereafter.77

Likewise, Switzerland opened addiction maintenance clinics in the 1990s.78 Today, there are 23 such clinics treating more than 2,000 heroin‐​dependent persons.79 Predictably, the country has enjoyed a marked decline in communicable diseases as well as drops in incidences of crimes associated with drug use.80 And the percentage of participants maintaining full‐​time employment has tripled, while dependence upon welfare has declined dramatically.81 In turn, harm reduction efforts have grown in popularity. In 2008, 68 percent of Swiss voters approved a measure to incorporate addiction maintenance into the country’s official health policy.82

Portugal has implemented even more ambitious harm reduction measures and has achieved even greater success. By the end of the 20th century, a staggering 1 percent of Portugal’s population was hooked on heroin.83 In 2001, the government decriminalized possession and use (but not sale) of all drugs and invested heavily in treatment and social services.84 Portugal’s new philosophy was to treat drug users as patients, not criminals—to keep them “inside the health system, not outside of it.”85 And its efforts have worked. Portuguese rates of drug use remain relatively high, but rates of hard drug use have declined, with heroin use declining by an astounding two‐​thirds from its peak.86 More to the point, drug‐​related HIV infections plummeted more than 90 percent and overdose deaths fell 85 percent—to the lowest death rate in Western Europe and one‐​fiftieth the rate in the United States.87 Portugal may have adopted radical policies of decriminalization and harm reduction, but it is not tolerant of drugs rather, it is intolerant of death and all the other unintended consequences of prohibition. As Nicholas Kristof remarked, “Portugal may be winning the war on drugs—by ending it.”88

How, When, and Why Addiction Maintenance Works

Why have these international efforts proved so successful? First, they are finely targeted to the challenges facing dependent drug users and are designed deliberately to help those users at critical moments. Heroin and other opioids are prescribed only after the failure of other efforts—whether therapeutic interventions or criminal enforcement.89 Second, addiction maintenance promotes safety: the drugs must be consumed onsite—in comfortable but sterile settings with well‐​equipped medical personnel on hand, thereby minimizing risks of death and the diversion of opioids into criminal markets.90 Third, and perhaps most importantly, these efforts are oriented against the logic of prohibition.91

The goal of addiction maintenance is harm reduction—a reduction in the harms that flow from illicit drug markets, infectious diseases, overdoses, and criminal enforcement and punishment.92 And, because addiction maintenance is an intervention of last resort (not unlike “heroic” measures in medicine93), it promises to reduce harm for the most dependent users.94 For those for whom nothing has worked, addiction maintenance provides the possibility to stay off streets, with families, in jobs, and out of emergency rooms, hospitals, jails, and mortuaries.95

And, even though addiction maintenance is intended only to provide palliative care, there is some evidence that—under the right circumstances—it may reduce overall drug use.96 This would seem counterintuitive, of course. How could it be that free access to opioids might help dependent users get clean? Appreciate, first, the context in which drugs are most often abused. The environmental theory of addiction insists that pharmacology is only secondarily related to dependence.97 Chemicals have physiological effects to be sure, but plenty of drug users maintain relative free will to ingest without becoming dependent.98 Indeed, the vast majority of people who try even hard drugs avoid dependence.99 A small subset develop powerful compulsions, but the question of when and whether these compulsions take hold may depend more on an individual’s life circumstances than the chemical composition of the drug.100

This is the environmental theory of addiction;101 consider a series of animal studies.102 In an early set of studies, rats were placed alone in cages with food, water, and cocaine drips.103 In short order, most rats abandoned their food and water and fixated on the cocaine, consuming copious amounts until death.104 At first blush, the studies seemed to demonstrate the intensity of chemical hooks.105 But, decades later, social scientists replicated the studies with a clever twist: several rats were housed together in nurturing environments, not in isolation in sterile cages, and they were given ample opportunities to interact and socialize.106 These rats still experimented with the cocaine, but not to excess and less so over time.107 Consider also the many heroin‐​dependent American soldiers fighting in Vietnam who readily gave up substance abuse once they returned home safely.108 These men self‐​medicated against the horrors of war but were able to alter their behavior once the context changed.109 Like the drug‐​dependent soldiers in Vietnam, the first set of rats was self‐​medicating against pain and loneliness. The second set enjoyed meaningful lives, and those rats had less desire or compulsion to fill the void with self‐​harm.110

Now consider the life of a drug user under the framework of prohibition. The threat of criminal repercussions drives users underground in search of drugs of unknown quality and provenance while isolating them from the resources and support systems needed to address addiction. According to Gabor Maté, a doctor specializing in childhood trauma and addiction,

If I had to design a system that was intended to keep people addicted, I’d design exactly the system that we have right now… . I’d attack people and ostracize them… . The more you stress people, the more they’re going to use. The more you de‐​stress people, the less they are going to use. So to create a system where you ostracize and marginalize and criminalize people, and force them to live in poverty with disease, you are basically guaranteeing they will stay at it.111

Maté has been criticized for overstating the influence of isolation and trauma while underplaying pharmacological effects.112 But the Vancouver and European experiences suggest strongly that the isolation and trauma created by prohibition cause substantial harm. When these international municipalities and governments abandoned prohibition and focused instead on eliminating barriers to drug acquisition, drug users were better able to focus on self‐​improvement. Their ties to family, community, education, and employment were strengthened (or at least left intact). Thus, for instance, a Lancet study found that the majority of participants in Switzerland’s addiction maintenance clinics were able to pivot eventually to methadone or abstinence programs.113 Moreover, as Vancouver’s Downtown Eastside discovered, fewer people are likely to become drug dependent in the first instance once a neighborhood’s quality of life improves.

The conclusion is inescapable. Addiction need not be a terminal condition. And, for the most dependent, the most promising treatment may just be to feed the habit.114 If nothing else, addiction maintenance facilitates the process known as aging out.115 Heavy drug abuse and other risk‐​taking behaviors concentrate in populations of young adult men.116 As individuals mature, they tend to use less.117 The more stable people’s lives are, the likelier they are to age out more quickly.118 The takeaway is obvious: sometimes the best approach is patience—to wait out drug use, misuse, abuse, or dependence—and, in the interim, to minimize the damage done to the individual and his social network.

This is what addiction maintenance programs are designed to achieve. They try to keep the hopeless addict alive, relatively healthy, and socially integrated long enough to navigate, eventually, to the other side of the age divide—to steer clear of the most destructive and deadly byproducts of punitive prohibition.119

But isn’t the current opioid crisis a product of a prescription market and model? Drug manufacturers pushed opioids on doctors.120 And “pill mills”—the pharmacies and physicians that overprescribed and overdispensed medications—pushed opioids on patients.121 In short, America already subscribed to a drug‐​licensing regime, and it led to lives ruined or ended prematurely, families and communities splintered, and support networks broken down.122 If prescriptions and addiction maintenance are so promising, what went so wrong?

The short answer is that recent American experience cannot be understood as addiction maintenance. Under addiction maintenance, people who abuse opioids and who have failed to respond to other kinds of treatment, including methadone maintenance, would be admitted into medically supervised clinics and provided pharmaceutical‐​grade narcotics in amounts calibrated to reduce the harms of obtaining and using drugs from illicit markets while maintaining social and physical well‐​being.123 The American approach is, in fact, the opposite of addiction maintenance. Our prevailing licensing regime permits doctors to prescribe opioids only until patients become dependent.124 A recently passed Michigan statute captures this, defining good‐​faith practice as “the prescribing or dispensing of a controlled substance . . . in the regular course of professional treatment . . . for a pathology or condition other than that individual’s physical or psychological dependence upon or addiction to a controlled substance [italics added].”125 Once patients get hooked, patient‐​centered care is displaced and the protocols of mandatory tapering and forced cessation imposed, backed by threat of criminal penalties.126

Use‐​reduction logic might seem simple enough: fewer prescriptions for pills should correspond with less use by the drug dependent. And, indeed, prescription opioid use has dropped dramatically in recent years.127 Prescriptions peaked in 2012 and have fallen since.128 In 2017 alone, they plummeted 10 percent, the sharpest decline in a quarter century.129 But current enforcement efforts have succeeded only in minimizing prescription drug use and diverting prescription drugs and prescription drug users into illicit markets.130 Put simply, a downtick in prescription drug availability translates into an uptick in demand for street‐​manufactured drugs. Patients become criminal buyers, the price of heroin undercuts illicitly diverted pharmaceuticals, syringes replace pills, and dealers cut drugs with fentanyl and other dangerous chemicals. According to Johann Hari:

If I am an American who has developed an Oxycontin addiction, as soon as my doctor realizes I’m an addict, she has to cut me off. She is allowed to prescribe to treat only my physical pain—not my addiction.… That’s when, in desperation, I might hold up a pharmacy with a gun, or go and buy unlabeled pills from street dealers. Most of the problems attributed to prescription drugs in the United States … begin here, when the legal, regulated route to the drug is terminated.… The prescription drug crisis doesn’t discredit legalization—it shows the need for it.131

The data bear out Hari’s claims. As opioid prescriptions have plummeted, opioid‐​linked deaths have skyrocketed.132 Street trade produces unreliable doses that fluctuate in quality and strength. One dealer may find it profitable to dilute a batch and sell more. Another dealer may cut costs by adding cheap fentanyl—an extremely potent and highly lethal synthetic opioid for which even seasoned opioid users may lack tolerance. More to the point, dealers may not even be aware of the purity and potency of their own unlabeled and unregulated goods. And comparatively milder prescription drugs, which were previously more accessible on pharmacy shelves, are often just too expensive and bulky for street‐​level sellers to keep in stock. “Just as when all legal routes to alcohol were cut off, beer disappeared and whisky won, when all legal routes to opiates are cut off, Oxy disappears, and heroin prevails. This isn’t a law of nature.… [It’s] drug policy.”133

Recent reform efforts have made the problem only worse. The current war on opioids is, like the first war on drugs, a war on physicians. In the words of former attorney general Jeff Sessions, “‘We’re going to target those doctors.’”134 In January 2018, the Drug Enforcement Agency (DEA) initiated a “surge” in efforts to shut down pill mills.135 The next month, the Justice Department started a task force to pursue manufacturers and distributors.136 According to a press release, “The Department will … use all criminal and civil tools at its disposal to hold distributors such as pharmacies, pain management clinics, drug testing facilities, and individual physicians accountable for unlawful actions … to prevent diversion and improper prescribing.”137 In March 2018, the administration announced plans to cut opioid prescriptions by a third within three years, and the DEA initiated new drug‐​production quotas, ultimately producing dramatic opioid shortages.138 In June 2018, Sessions announced charges against 162 individuals, including physicians, for crimes related to prescribing and distributing prescription opioids.139 And, even before this recent crackdown, the DEA had increased actions against doctors from 88 in 2011 to 479 in 2016.140

The escalation and crackdown are not unique to federal law enforcement. The Centers for Disease Control and Prevention (CDC) has promulgated its own guidelines for prescribing higher dosages.141 Initially, these were recommendations only, but several states and medical boards have turned those guidelines into rigid rules, using the CDC template to enact statutory and regulatory limits that help define what constitutes medical malpractice and criminal wrongdoing.142 Likewise, public and private insurers have imposed their own tapering protocols that expand tracking, interfere in the physician‐​patient relationship, and curtail further the responsible practice of individualized medicine.143

In turn, physicians have stopped treating patients whose health could genuinely benefit from large or long‐​term doses of prescription opioids. Consider the DEA’s pursuit of Forest Tennant, a prominent California physician who faced criminal investigation for atypical prescribing.144 Tennant specialized in severe chronic pain and was world‐​renowned for palliative care, often at the end of life.145 He had evidence‐​based reasons for prescribing such large quantities of opioids.146 Nevertheless, law enforcement successfully pushed Tennant into early retirement, leaving his patients to suffer without effective pain management.147

This is overdeterrence in action—another example of how prohibition chills socially valuable conduct at the margins.148 Indeed, in some states, the wait to see a qualified pain management specialist has increased to a year or longer.149 And it stands to reason that some of the most ethical doctors may be the most easily dissuaded from prescribing opioids consistent with patients’ actual needs; because these physicians are likelier to be comparatively risk averse, they are likelier to overcorrect in order to steer well clear of increasingly pronounced criminal justice threats and consequences. Moreover, they are likelier to be aware of (and comply with) the heightened recordkeeping requirements that law enforcement may use to trawl for patient and physician targets. At a certain point, it’s just not worth the effort. As one primary care doctor put it, “‘I will no longer treat chronic pain. Period… . There is too much risk involved.’”150

The Future of Reform

Meaningful domestic drug reform has only ever arisen from the bottom up. Take the example of syringe exchanges. Starting in Europe in the 1980s, activists experimented with exchanges as a response to the deadly epidemic of HIV/AIDS.151 American reformers took note, but federal and state governments worked actively against such initiatives. The DEA, for example, had previously promulgated the Model Drug Paraphernalia Act, which provided a template for 46 states to criminalize the manufacture, possession, or distribution of drug paraphernalia, broadly defined.152 Moreover, the federal government refused to fund syringe exchanges until they were proven “safe and effective” (and, of course, it refused also to fund research into the question).153 Indeed, Sen. Jesse Helms (R-NC) equated any public effort to implement a syringe exchange to government‐​supported drug abuse.154 Nevertheless, activists persisted in doing what they could, typically underground.155 Over time, some mainstream stakeholders even began to buy in. Ultimately, a number of municipal and state authorities authorized syringe‐​exchange programs, maneuvering polit­ically and legally to prevent pushback.156 By 2015, even the federal government had lifted its funding ban—albeit only partially (and more than a quarter century too late).157 Overall, reform efforts proved successful.

Consider the example of medical cannabis. Today, a majority of states permit at least some form of medical use.158 But these statutory public health interventions were slow in coming, even though, as early as the 1970s, it was already well established that cannabis could quell cancer patients’ nausea and stimulate their appetites.159 Over the next 20 years, patients and advocates raised awareness that cannabis could also alleviate suffering from other illnesses and afflictions—glaucoma, AIDS‐​related wasting syndrome, epilepsy, neuropathic pain, and the side effects of ingesting certain drug cocktails.160

Nevertheless, the federal government remained largely intransigent. In 1996, after California voters passed the Compassionate Use Act by proposition, federal authorities threatened physicians with civil and criminal penalties merely for recommending medical cannabis.161 Even today, the Controlled Substances Act classifies marijuana as a Schedule I drug—a substance purported to have no therapeutic benefits and a high potential for abuse.162 Simply put, federal law continues to criminalize cannabis.163

In spite of these hurdles, activists found a way to build a grassroots movement around medical cannabis, establishing a collection of underground dispensaries.164 Municipalities and states began to follow their lead, primarily, at first, by citizen‐​initiated resolutions, referendums, and propositions.165 Lawmakers only began to act once the issue of medical cannabis had become obviously expedient.166 Until then, the path to meaningful reform was direct democracy and direct action.

To these examples, we could add the drug‐​court movement, which now boasts over 2,000 courts currently operating nationwide.167 In the interest of full disclosure, we should make it clear that we, as authors, are deeply skeptical of the ability of drug courts to provide appropriate treatment and to function effectively as an alternative to incarceration (much less to avoid the collateral harms of the drug war).168 The drug‐​court model embraces and perpetuates the same prohibitionist and coercive paradigm of abstinence that we believe is so misguided. The movement operates within criminal justice, retaining the threat of punishment as a backstop for the noncompliant participant. Disappointingly, but perhaps unsurprisingly, many leading drug‐​court advocates have tended, therefore, to publicly oppose more ambitious drug policy reform, including the decriminalization of cannabis (even for medical use),169 reduction of felony possession offenses to misdemeanor or noncriminal offenses,170 and acceptance of (and reliance upon) medication‐​assisted treatments.171

The origins of the drug‐​court movement can be traced to a small handful of ground‐​level advocates (in this case, county judges and local law enforcement) who could no longer countenance the most egregious excesses of the drug war, such as lengthy jail and prison sentences for low‐​level, nonviolent drug offenders.172 With no other viable option, these officials began to experiment, first quietly, then vocally, with alternative judicial interventions intended to avoid draconian penalties for chemically dependent persons.

These examples illustrate the failure of the drug war and the role of grassroots activism in driving meaningful change. Although there has been some progress, such issues remain with respect to the opioid epidemic. Until relatively recently, federal and state laws largely prevented most people from preemptively gaining access to naloxone, an opioid antagonist, which reverses overdoses.173 Naloxone (trade name Narcan) is called the Lazarus drug for a good reason: injecting naloxone into a person’s bloodstream revives the sufferer by counteracting respiratory distress.174 For a long time, however, possession of naloxone was limited principally to emergency medical technicians and emergency room staff.175 Thus its benefits could reach only those overdose victims who lived long enough to see the inside of an ambulance or hospital.

Technically, some physicians could still prescribe naloxone, but any such efforts were resisted by public officials, law enforcement, and even many within the medical community.176 In a classic example, opponents of naloxone relied upon the argument that ready access to naloxone would encourage opioid users (antidote in hand) to use drugs more often and more recklessly.177 Naloxone is neither an addictive nor mind‐​altering chemical compound, and it is incapable of recreational abuse.178 It is, first and foremost, a lifesaver. To withhold it is to endorse the view that death is an appropriate punishment for those who overdose.

Enter the street activists. Piggybacking on the highly successful work of a syringe exchange program in Chicago, activists began distributing naloxone to syringe‐​exchange clients and taught them how to administer naloxone to reverse an overdose.179 Days after distribution of the first naloxone dose, a “save” was recorded.180 Hundreds and then thousands of saves followed.181 Other syringe exchanges took note of the Chicago experiment, as did local public health departments. In short order, communities across the country began to distribute (or turn a blind eye to the distribution of) naloxone; municipal and state‐​level law and policy reform followed thereafter. By July 2017, all 50 states and the District of Columbia had taken legal steps to increase access to naloxone.182

Four dynamics describe these drug policy reforms. First, until harm reduction interventions are well established, public officials and law enforcement agents are typically part of the problem, not the solution. Policymakers and professionals initially either opposed pragmatic harm reduction measures or stayed mum, fearing backlash.183 The enforcers of the drug war participate in a multibillion‐​dollar criminal justice‐​industrial complex, just as drug traffickers participate (illicitly and licitly) in multibillion‐​dollar drug‐​distribution and pharmaceutical‐​industrial complexes.184 In each of these markets, there is a lot at stake. Criminal justice has its jail and prison cells, paid prosecutors and judges, and police, probation, and corrections officers. The prescription drug industry has its drug representatives, scientific researchers, public relations professionals, and political lobbyists. Organized drug crime has its guns and safe houses, gang members, foot soldiers, and street dealers. The pressure is tremendous to keep feeding the drug‐​war machinery. No surprise, then, that institutional elites tend to make bad insurgents.

Second, and relatedly, public health innovations typically start underground. For years—without any change in local, state, or federal law—sterile syringes were exchanged, medical marijuana was ingested, and naloxone was distributed and injected. If “Just Say No” is the mantra of the drug war, then the ethos of drug reform is Nike’s motto, “Just Do It.” Grassroots activists have proven to be willing to risk everything to defy the status quo by purposefully violating drug laws.185 For these advocates, protecting and saving lives is worth the gamble.

Third, if and when de jure reform occurs, it often bubbles up from below. Long before legislators find the motivation or courage to enact statutes, community activists, advocates, and organizers persuade independent‐​minded city councilors and mayors to declare states of emergencies—authorizing, for instance, syringe exchanges to combat HIV/AIDS.186 Local police and prosecutors exercise discretion to look the other way when grassroots activists disobey criminal laws against the possession of naloxone.187 City officials use local initiatives to push law enforcement to deprioritize the criminal possession of small amounts of marijuana.188 And the public pass popular resolutions and referendums.189 Eventually, states may follow suit—but only after witnessing what has worked locally.

Fourth, all the while, the federal structure stays largely intact. Its orientation remains prohibition first. At best, federal officials may tolerate local experimentation. But the federal law remains criminal law—the Controlled Substances Act and other punitive statutes like it. Even today, federal support for syringe exchanges is largely passive. Likewise, the federal government continues to oppose medical cannabis. And, perhaps more importantly, it continues to stifle medical‐​cannabis research,190 thereby keeping technically true the hollow claim that the substance has no proven medical benefits.191

It is against this backdrop—and within this framework—that we should consider addiction maintenance. Addiction maintenance is more than a theoretical possibility; it is a historical and international reality. But, as a domestic practice, it remains a distant prospect. How distant is unclear. By nature, underground enterprises are hard to track. It could well be that an American addiction maintenance clinic is operating illegally already—either with a wink and nod from local officials or completely underground. The lives of heroin‐​dependent persons rely upon access to pharmaceutical‐​grade heroin instead of toxic street‐​corner junk.

More to the point, a precursor to the addiction maintenance clinic has already begun to find traction—the safe site, or supervised injection facility, which does not supply drugs but provides a space for relatively safe consumption.192 For some time, it has been an open secret that at least one unsanctioned supervised injection facility has operated within the United States.193 And activists have lobbied to bring underground safe sites to the surface.194 Even the American Medical Association has come aboard, declaring support for the model.195 Likewise, the idea has spread to progressive prosecutors and police commissioners.196 Just this past year, public health advocates in Philadelphia, with the support of city leaders, formed a nonprofit called Safehouse to open the first above‐​ground supervised injection facility in the country.197 Predictably, state officials have opposed the effort with claims that it cannot be done under federal law (though Pennsylvania’s governor has signaled that he may keep his hands off the effort).198 Federal officials have responded predictably, flexing drug‐​war muscles with threats to enforce the so‐​called crack house law against any safe site should one try to open aboveground.199 In the same vein, the Justice Department is currently planning to appeal a district court ruling that the Controlled Substances Act would not apply to Safehouse’s operations.200 Notwithstanding the federal resistance, we believe it likely that licit supervised injection facilities will open domestically—if not in Philadelphia, then somewhere else sometime soon.201

That is what happened with syringe exchanges and medical cannabis. More to the point, that is what happened in Vancouver where underground efforts by street activists eventually produced a legally authorized supervised injection facility.202 And that facility, in turn, helped produce an aboveground addiction maintenance clinic—a site where individuals now go to get their fix without needlessly jeopardizing their lives and liberty or, for that matter, public safety and order.


The drug‐​free society is a pipe dream. If, instead, we were to acknowledge that drugs are an often (but not always) unfortunate fact of life, we might come to regard drug misuse, abuse, dependence, and addiction for what they are—questions of health, not morality, and of social policy, not penology. Our success would not be measured by our proximity to a drug‐​free America but whether we have minimized drug‐​related deaths, disease, crime, and suffering, whether we have improved health and welfare, and whether we have preserved and expanded autonomy and dignity.

We remain doubtful that American society and its legal and medical institutions can reorient wholly from a criminal‐​legal model to a public health model. The logic of prohibition has enjoyed too much dominance for far too long. Few medical schools meaningfully incorporate addiction treatment into core curricula, and few new doctors choose to specialize in addiction medicine.203 Perhaps doctors have avoided practicing addiction medicine because the professional and legal risks are too great. Moreover, until relatively recently, insurance providers could legally refuse to cover addiction treatment—at least, more readily than other accepted medical interventions.204 But, for many in the industry, the problem is likewise cultural. Although many medical professionals have been on the front lines of the most ambitious drug policy reforms, it is still not uncommon to encounter doctors who harbor the same attitudes as prohibitionists.

However, precisely because culture plays such an influential role in drug policy and medical practice, there is a silver lining to the immediate epidemic. The opioid crisis has awoken a previously indifferent America to the failings of prohibition.205 We are hopeful, but not overly so, that this awakening could translate to meaningful change all the way up to the federal level. We are especially encouraged—and somewhat surprised—that the Senate, by a remarkable vote of 99 to 1, recently passed sweeping legislation that could make it easier for doctors to prescribe suboxone (buprenorphine) and other forms of medication‐​assisted treatment for addiction.206 Again, interest convergence has a way of making the seemingly impossible suddenly possible, even if not for entirely admirable reasons.207

But these welcome developments are counterbalanced by more conventional resistance, like the Justice Department’s recent crackdown against prescribing doctors. All in all, we expect to see mainly street‐​level activism and politically popular local initiatives but too few positive steps beyond that. The logic of prohibition will continue to predominate, and the machinery of criminal punishment will continue to churn.208 Still, we offer this pragmatic six‐​point plan for addressing our current opioid crisis:

  1. Grant 911 amnesty from arrest for all drug offenses for all individuals who contact authorities to report overdoses or people in need of aid.209
  2. Make naloxone available without a prescription at pharmacies, fire stations, public libraries, police stations, hospitals, jails and prisons, and supervised injection facilities.210
  3. Make pill and powder testing available to assess drug purity and to detect the presence of fentanyl and other dangerous compounds as a means to enable drug users to make informed choices about whether and how to use substances.211
  4. Make medication‐​assisted treatment available with prescription, within and beyond clinical settings, for all individuals who require it, inmates included, without forced detoxification after fixed time periods.212
  5. Make supervised injection facilities, drug consumption rooms, and syringe exchanges available in areas of concentrated injection drug use.213
  6. Make physician‐​supervised addiction maintenance programs available with prescription for individuals for whom other forms of medication‐​assisted therapy have failed.

The empirical and anecdotal evidence is persuasive that these interventions will save lives, alleviate suffering, and lessen drug‐​related crime.

Criminal law is the wrong tool for addressing the opioid epidemic. People are dying in record numbers, and we must acknowledge and abandon our addiction to punishment and broaden our legal horizons to adopt measures proven to reduce and avoid harms related to both drug use and enforcement of the drug war.214


Bowers, Josh, and Daniel Abrahamson. “Kicking the Habit: The Opioid Crisis and America’s Addiction to Prohibition.” Policy Analysis No. 894, Cato Institute, Washington, DC, June 29, 2020. https://​doi​.org/​1​0​.​3​6​0​0​9​/​P​A.894.


Download the Policy Analysis

About the Authors
Josh Bowers is the F. D. G. Ribble Professor of Law at the University of Virginia School of Law. Daniel Abrahamson founded the Office of Legal Affairs of the Drug Policy Alliance.

Many thanks to Rebecca Rubin for her exceptional research assistance.

1. Drug Policy Alliance, “A Brief History of the Drug War,”

2. “The Controlled Substances Act,” United States Drug Enforcement Administration,

3. Bettina Muenster and Jennifer Trone, Why Is America So Punitive? A Report on the Deliberations of the Interdisciplinary Roundtable on Punitiveness in America (New York: John Jay College of Criminal Justice, 2015).

4. Josh Bowers, “Legal Guilt, Normative Innocence, and the Equitable Decision Not to Prosecute,” Columbia Law Review 110, no. 7 (November 2010): 1655, 1691. “Legal formalism may produce a kind of childishness—an inability to interact with the uncertainties of the real world and an eagerness to retreat to ‘structures of authority’ that substitute hollow make-believe for life in fact. Put simply, legal training facilitates incuriosity by emphasizing hierarchical and rule-bound thinking.” Quotes Richard A. Posner, How Judges Think (Cambridge, MA: Harvard University Press, 2008); and Josh Bowers, “Probable Cause, Constitutional Reasonableness, and the Unrecognized Point of a ‘Pointless Indignity,’” Stanford Law Review 66, no. 5 (May 2014): 987, 1048–49 (discussing legal culture and the lawyer’s turn of mind).

5. “Her Causes,” Ronald Reagan Presidential Foundation and Institute (discussing Nancy Reagan’s 1980s “Just Say No” advertising campaign).

6. Jenae Addison, “How Racial Inequity Is Playing Out in the Opioid Crisis,” NewsHour, PBS (July 18, 2019); and Melissa Healy, “Why Opioids Hit White Areas Harder: Doctors There Prescribe More Readily, Study Finds,” Los Angeles Times (February 11, 2019).

7. Derrick A. Bell Jr., “Brown v. Board of Education and the Interest-Convergence Dilemma,” Harvard Law Review 93, no. 3 (January 1980): 518, 523.

8. By way of explanation, harm-reduction models focus on minimizing the negative social, economic, and physical externalities that flow from human behaviors. Ingrid Van Beek, “Harm Reduction—An Ethical Imperative,” Addiction 104, no. 3 (2009): 341, 343. On the other hand, drug prohibition focuses on abstinence—also termed “use reduction” or “prevalence reduction”—backed by the cudgel of criminal justice. Robert J. MacCoun, “Moral Outrage and Opposition to Harm Reduction,” Criminal Law and Philosophy 7, no. 1 (January 2013): 83–84; and Robert J. MacCoun and Peter Reuter, Drug War Heresies: Learning from Other Vices, Times, and Places (Cambridge: Cambridge University Press, 2001). By way of analogy, imagine two methods for promoting sexual health—providing free condoms or criminalizing contraceptives. Harm reduction describes the first approach; prohibition describes the second.

9. Alfred R. Lindesmith, “The Addict and the Law,” Indiana Law Journal 40, no. 3 (1965): 464–68 (discussing the history of federal drug policy in the United States).

10. Alexander Cockburn and Jeffrey St. Clair, Whiteout: The CIA, Drugs and the Press (London: Verso, 1999), p. 71.

11. Cockburn and St. Clair, Whiteout.

12. Johann Hari, Chasing the Scream: The First and Last Days of the War on Drugs (New York: Bloomsbury, 2015); and Cockburn and St. Clair, Whiteout, p. 35.

13. Cockburn and St. Clair, Whiteout, p. 226.

14. Ellen M. Weber, “Failure of Physicians to Prescribe Pharmacotherapies for Addiction: Regulatory Restrictions and Physician Resistance,” Journal of Health Care Law & Policy 13, (2010): 49, 56. “The medical community viewed addiction as a medical problem, and physicians prescribed opioid medications for the care of addicted patients without legal restrictions.”

15. David T. Courtwright, “The Hidden Epidemic: Opiate Addiction and Cocaine Use in the South, 1860–1920,” Journal of Southern History 49, no. 1 (1983): 57–72.

16. Courtwright, “Hidden Epidemic.”

17. Weber, “Failure of Physicians,” p. 34 (quoting Henry Smith Williams, “The doctor knows just what should be done . . . that he has but to write a few words on the prescription blank that lies at his elbow, and the patient . . . will receive the remedy that would restore him miraculously to a semblance of normality”); and Henry Smith Williams, Drug Addicts Are Human Beings (Washington: Shaw Publishing, 1938).

18. Weber, “Failure of Physicians,” p. 17 (describing the racist belief, prevalent during the era, that marijuana made black men “forget the appropriate racial barriers—and unleased their lust for white women”).

19. Alyssa Pagano, “The Racist Origins of Marijuana Prohibition,” Business Insider, March 2, 2018; Michael Woodiwiss, “Reform, Racism, and Rackets: Alcohol and Drug Prohibition in the United States,” in The Control of Drugs and Drug Users: Reason or Reaction?, ed. Ross Coomber (Amsterdam: OPA, 1998), 13–30; Edward Huntington Williams, “Negro Cocaine ‘Fiends’ Are a New Southern Menace: Murder and Insanity Increasing among Lower Class Blacks Because They Have Taken to ‘Sniffing’ Since Deprived of Whisky by Prohibition,” New York Times, February 8, 1914 (detailing racist allegation of a “negro . . . ‘running amuck’ in a cocaine frenzy, [who] had [purportedly] attempted to stab a storekeeper, and was [allegedly] . . . ‘beating up’ the various members of his own household”); and “How Did We Get Here? History Has a Habit of Repeating Itself,” The Economist, August 14, 2018 (describing early 20th-century racist perception of “drug-crazed, sex-mad negroes” and drug-addicted “Chinese ‘coolies’ brought into California to build railways and dig mines”).

20. “Cocaine Sniffers: Use of the Drug Increasing among Negroes in the South,” New York Daily Tribune, June 21, 1903, p. 11; and David F. Musto, The American Disease: Origins of Narcotic Control, 3rd ed. (New York: Oxford University Press, 1999) (describing “fantasies characterized by white fear, not the reality of cocaine’s effect” that “coincided with the peak of lynchings, legal segregation, and voting laws all designed to remove political and social power from [black Americans]”).

21. Weber, “Failure of Physicians,” pp. 17–32.

22. John Helmer and Thomas Vietorisz, Drug Use, the Labor Market and Class Conflict (Washington: Drug Abuse Council Inc., 1974) (finding that whites used drugs at higher rates than blacks in early 20th-century America); and “Criminal Justice Fact Sheet,” National Association for the Advancement of Colored People,

23. Courtwright, “Hidden Epidemic”; and Musto, American Disease, p. 57.

24. Hari, Chasing the Scream; and Weber, “Failure of Physicians,” pp. 35–36.

25. William J. Stuntz, “Race, Class, and Drugs,” Columbia Law Review 98, no. 7 (1998): 1795.

26. Harrison Narcotics Tax Act of 1914, Pub. L. No. 63-223, 38 Stat. 785 (December 17, 1914) (repealed 1970).

27. Musto, American Disease, pp. 59, 151; Harrison Narcotics Tax Act of 1914; Hari, Chasing the Scream; Weber, “Failure of Physicians,” p. 37; Courtwright, “Hidden Epidemic”; Weber, “Failure of Physicians”; Pagano, “The Racist Origins of Marijuana Prohibition,” pp. 58–59 (“Federal and state health officials and local law enforcement, beginning around 1912, created maintenance clinics in a dozen states that would prescribe medication in an effort to prevent suffering related to addiction and wean individuals from their drug use through the gradual reduction of dosage.”); and Alex Kreit, Controlled Substances: Crime, Regulation, and Policy (Durham, NC: Carolina Academic Press, January 2013), pp. 739–40 (discussing addiction maintenance).

28. Courtwright, “Hidden Epidemic”; and Musto, American Disease, p. 60.

29. Weber, “Failure of Physicians”; and Pagano, “The Racist Origins of Marijuana Prohibition,” p. 59.

30. Musto, American Disease; Hari, Chasing the Scream, pp. 151, 156–78

31. Hari, Chasing the Scream; Weber, “Failure of Physicians,” p. 37.

32. Thomas M. Quinn and Gerald T. McLaughlin, “The Evolution of Federal Drug Control Legislation,” Catholic University Law Review 22, no. 3 (1973): 586, 595.

33. Jin Fuey Moy v. United States, 254 U.S. 189, 194 (1920).

34. Webb v. United States, 249 U.S. 96, 99–100 (1919). (“[T]o call such an order for the use of morphine a physician’s prescription would be so plain a perversion of meaning that no discussion of the subject is required.”)

35. Jin Fuey Moy v. United States, 254 U.S. at 194 (holding that the physician’s exemption did not include “a distribution intended to cater to the appetite or satisfy the craving of one addicted to the use of the drug,” and noting that a “‘prescription’ issued” for addiction maintenance “protects neither the physician who issues it, nor the dealer who knowingly accepts and fills it”).

36. United States v. Behrman, 258 U.S. 280, 288 (1922).

37. Rufus King, The Drug Hang-Up: America’s Fifty-Year Folly, 1st ed. (New York: W. W. Norton, 1972), p. 42.

38. Linder v. United States, 268 U.S. 5, 18 (1925). “What constitutes bona fide medical practice must be determined upon consideration of evidence and attending circumstances.”

39. Lindesmith, “Addict”; and Weber, “Failure of Physicians,” pp. 6–7.

40. “Symposium: The Legal Construction of Norms,” Virginia Law Review 86 (2000): 1577–2021.

41. Weber, “Failure of Physicians”; and Pagano, “The Racist Origins of Marijuana Prohibition,” p. 56.

42. See Pagano, “The Racist Origins of Marijuana Prohibition,” pp. 58–60. (“The American Medical Association issued a resolution in 1920 opposing ambulatory maintenance clinics and condemning the use of heroin, which sanctioned the further prosecution of physicians who continued to prescribe maintenance medication.”)

43. Pagano, “The Racist Origins of Marijuana Prohibition,” p. 60.

44. “Eighteenth Amendment,” Encyclopedia Britannica.

45. Weber, “Failure of Physicians,” p. 38; and Pagano, “The Racist Origins of Marijuana Prohibition,” pp. 57–59 (discussing the federal government’s ever-more vigorous enforcement of the Harrison Act after alcohol prohibition); and Hari, Chasing the Scream.

46. Quinn, Evolution of Federal Drug Control; Lindesmith, “Addict,” pp. 594–95; Michael Nedelman, “Doctors Increasingly Face Charges for Patient Overdoses,” CNN, July 31, 2017; and Pia Malbran, “What’s a Pill Mill?,” CBS News, May 31, 2007.

47. Khary K. Rigg, Steven P. Kurtz, and Hilary L. Surratt, “Patterns of Prescription Medication Diversion among Drug Dealers,” Drugs: Education, Prevention and Policy 19, no. 2 (2012): 145–55.

48. Quinn, Evolution of Federal Drug Control; and Lindesmith, “Addict,” p. 595.

49. Peter Reuter, Can Heroin Maintenance Help Baltimore? (Baltimore: Abell Foundation, January 2009). (“A small but growing number of Western nations are experimenting with heroin maintenance.”)

50. Hari, Chasing the Scream; Weber, “Failure of Physicians,” pp. 197–202; and Matthew Power, “The Alleys of Vancouver,” Slate, February 3, 2010.

51. Hari, Chasing the Scream; and Weber, “Failure of Physicians,” pp. 202–3.

52. Hari, Chasing the Scream, p. 200. “Suddenly, VANDU was an international news story . . . from the BBC to the New York Times.”

53. Hari, Chasing the Scream, pp. 200–2.

54. Hari, Chasing the Scream, pp. 202–3.

55. German Lopez, “The Case for Prescription Heroin: Vancouver Gives Heroin to People Suffering from Addiction—and It Works,” Vox, June 12, 2017; Hari, Chasing the Scream; Weber, “Failure of Physicians,” p. 219; and John Strang, Teodora Groshkova, and Nicola Metrebian, New Heroin-Assisted Treatment—Recent Evidence and Current Practices of Supervised Injectable Heroin Treatment in Europe and Beyond, EMCDDA Insights Series no. 11 (Luxembourg City, Luxembourg: Publications Office of the European Union, 2012).

56. JoNel Aleccia, “As Seattle Eyes Supervised Drug-Injection Sites, Is Vancouver a Good Model?,” Seattle Times, November 30, 2016.

57. Canada (Attorney General) v. PHS Community Services Society, [2011] 3 S.C.R. 134, 147–8 (describing the work and impact of VANDU); and Robert Matas, “B.C. Drug Deaths Hit a Low Not Seen in Years,” Globe and Mail, December 9, 2008.

58. Evan Wood et al., “Changes in Public Order after the Opening of a Medically Supervised Safer Injecting Facility for Illicit Injection Drug Users,” Canadian Medical Association Journal 171, no. 7 (2004): 731, 733. (“Our observations suggest that the establishment of the safer injecting facility has resulted in measurable improvements in public order, which in turn may improve the livability of communities and benefit tourism while reducing community concerns stemming from public drug use and discarded syringes.”)

59. Drug Policy Alliance, Drug Courts Are Not the Answer: Toward a Health-Centered Approach to Drug Use (New York: Drug Policy Alliance, March 21, 2011) (describing Canadian “opioid-maintenance therapy” that has “decreased drug use and crime”).

60. Sam Cooper, “‘I Don’t Want to Die Here’: Residents Buoyed by Stats Showing People in Poorest Area Living Longer,” Province, September 7, 2012.

61. Hari, Chasing the Scream; Weber, “Failure of Physicians,” pp. 170–75; and accompanying text discussing the environmental theory of addiction.

62. Robert Weiss, “The Opposite of Addiction Is Connection: New Addiction Research Brings Surprising Discoveries,” Psychology Today, September 30, 2015.

63. Lopez, “Case for Prescription Heroin.”

64. Lopez, “Case for Prescription Heroin.”

65. Lopez, “Case for Prescription Heroin.”

66. Lopez, “Case for Prescription Heroin.”

67. Lopez, “Case for Prescription Heroin”; Hari, Chasing the Scream; and Weber, “Failure of Physicians.”

68. Lopez, “Case for Prescription Heroin”; Josh Bowers, “What If Nothing Works? On Recidivism, Crime Licenses, and Public Health,” forthcoming (reexamines recidivism through a public-health lens).

69. Lopez, “Case for Prescription Heroin.”

70. Lopez, “Case for Prescription Heroin.”

71. Lopez, “Case for Prescription Heroin.”

72. See Weber, “Failure of Physicians to Prescribe Pharmacotherapies for Addiction: Regulatory Restrictions and Physician Resistance,” and accompanying text (comparing harm-reduction and use-reduction approaches).

73. Lopez, “Case for Prescription Heroin”; and Hari, Chasing the Scream.

74. Lopez, “Case for Prescription Heroin.”

75. Lopez, “Case for Prescription Heroin”; and Hari, Chasing the Scream.

76. Hari, Chasing the Scream; Weber, “Failure of Physicians,” p. 210.

77. Linnet Myers, “Europe Finds U.S. Drug War Lacking in Results,” Chicago Tribune, November 2, 1995.

78. Hari, Chasing the Scream; Weber, “Failure of Physicians,” p. 219; and John Strang, Teodora Groshkova, and Nicola Metrebian, New Heroin-Assisted Treatment—Recent Evidence and Current Practices of Supervised Injectable Heroin Treatment in Europe and Beyond, EMCDDA Insights Series no. 11 (Luxembourg City, Luxembourg: Publications Office of the European Union, 2012).

79. Gaelle Faure, “Why Doctors Are Giving Heroin to Heroin Addicts,” Time, September 28, 2009.

80. Hari, Chasing the Scream; Weber, “Failure of Physicians,” p. 221 (notes drop in HIV infections caused by injection drug use from 68 to 5 percent); Joanne Csete and Peter J. Grob, “HIV and the Power of Pragmatism: Lessons for Drug Policy Development,” International Journal of Drug Policy 23, no. 1 (2012): 82 (noting drop in hepatitis infections caused by injection drug use from 51 to 10 percent); and Denis Ribeaud, “Long-Term Impacts of the Swiss Heroin Prescription Trials on Crime of Treated Heroin Users,” Journal of Drug Issues 34, no. 1 (2004): 163 (noting 50 percent reduction in vehicle thefts among participants).

81. Hari, Chasing the Scream; and Weber, “Failure of Physicians,” p. 222.

82. Kreit, Controlled Substances; and Cockburn and St. Clair, Whiteout, p. 740.

83. Luis M. Faria, “Portugal Solved Its Drug Crisis. Why Can’t America Do the Same?,” HuffPost, November 9, 2019; and Lauren Frayer, “In Portugal, Drug Use Is Treated as a Medical Issue, Not a Crime,” Morning Edition, NPR, April 18, 2017.

84. Faria, “Portugal Solved Its Drug Crisis”; and Frayer, “In Portugal, Drug Use Is Treated as a Medical Issue, Not a Crime.”

85. Faria, “Portugal Solved Its Drug Crisis.”

86. Hari, Chasing the Scream; Weber, “Failure of Physicians,” p. 249; and Faria, “Portugal Solved Its Drug Crisis.”

87. Hari, Chasing the Scream; Weber, “Failure of Physicians,” pp. 249–50, 268; Faria, “Portugal Solved Its Drug Crisis” (noting decline in death rate from one per day to only a couple per month); Naina Bajekal, “Want to Win the War on Drugs? Portugal Might Have the Answer,” Time, August 1, 2018; Caitlin Elizabeth Hughes and Alex Stevens, “What Can We Learn from the Portuguese Decriminalization of Illicit Drugs?,” British Journal of Criminology 50, no. 6 (July 2010): 999; Christopher Ingraham, “Why Hardly Anyone Dies from a Drug Overdose in Portugal,” Washington Post, June 5, 2015; Nicholas Kristof, “How to Win a War on Drugs,” New York Times, September 26, 2017; and Frayer, “In Portugal, Drug Use Is Treated as a Medical Issue, Not a Crime.”

88. Kristof, “How to Win” (Belgium, Germany, the Netherlands, Sweden, and Uruguay have undertaken similar harm-reduction reforms with similarly promising results); Hari, Chasing the Scream; Weber, “Failure of Physicians,” pp. 264–73; and Shirley Haasnoot, “Dutch Drug Policy, Pragmatic as Ever,” The Guardian, January 3, 2013.

89. Lopez, “Case for Prescription Heroin”; and Bowers, “What If Nothing Works?”

90. Lopez, “Case for Prescription Heroin”; and Bowers, “What If Nothing Works?”

91. Lopez, “Case for Prescription Heroin”; Bowers, “What If Nothing Works?”; and Harry G. Levine and Craig Reinarman, “From Prohibition to Regulation: Lessons from Alcohol Policy for Drug Policy,” Millbank Quarterly 69, no. 3 (1991): 461, 464.

92. Julia Lowe Behr, “Methadone Maintenance Therapy for Opioid Addiction,”, Clinician Reviews, June 18, 2008.

93. Thomas Lathrop Stedman, ed., The American Heritage Stedman’s Medical Dictionary, 2nd ed. (Boston: Houghton Mifflin Company, September 2004). Defines “heroic” measures as last-ditch efforts to address a medical problem.

94. Lopez, “Case for Prescription Heroin”; and Bowers, “What If Nothing Works?”

95. Lopez, “Case for Prescription Heroin”; and Bowers, “What If Nothing Works?”

96. Josh Bowers, “Contraindicated Drug Courts,” UCLA Law Review 55 (2008): 801–02; and Lopez, “Case for Prescription Heroin,” p. 16.

97. Hari, Chasing the Scream; and Pagano, “The Racist Origins of Marijuana Prohibition,” pp. 170–75.

98. Bowers, “Drug Courts”; Malcolm Gladwell, The Tipping Point: How Little Things Can Make a Big Difference (London: Abacus, February 2002), pp. 234–38; and Gene M. Heyman, “Is Addiction a Chronic, Relapsing Disease?,” in Drug Addiction and Drug Policy: The Struggle to Control Dependence, eds. Philip B. Heymann and William N. Brownsberger (Cambridge, MA: Harvard University Press, 2001), p. 86.

99. Bowers, “Drug Courts”; and Hari, Chasing the Scream, p. 801.

100. Hari, Chasing the Scream, pp. 171–73.

101. Hari, Chasing the Scream.

102. Hari, Chasing the Scream, pp. 171–73.

103. Hari, Chasing the Scream.

104. Hari, Chasing the Scream, pp. 171–73.

105. Hari, Chasing the Scream, p. 171.

106. Hari, Chasing the Scream, pp. 172–73.

107. Hari, Chasing the Scream.

108. Hari, Chasing the Scream, p. 173.

109. Hari, Chasing the Scream.

110. Hari, Chasing the Scream, p. 172.

111. Hari, Chasing the Scream, p. 166.

112. Stanton Peele, “The Seductive, but Dangerous, Allure of Gabor Maté,” Psychology Today, December 5, 2011.

113. Reuter, Can Heroin Maintenance Help Baltimore?

114. Gavin Bart, “Maintenance Medication for Opiate Addiction: The Foundation of Recovery,” Journal of Addictive Diseases 31, no. 3 (2012): 207.

115. Maia Szalavitz, “Most People with Addiction Simply Grow Out of It. Why Is This Widely Denied?,” Pacific Standard, October 1, 2014.

116. Laura Duberstein Lindberg, Scott Boggess, Laura Porter, and Sean Williams, Teen Risk-Taking: A Statistical Portrait (Washington: Urban Institute, June 2000).

117. Szalavitz, “Most People with Addiction”; and Lopez, “Case for Prescription Heroin.”

118. Szalavitz, “Most People with Addiction”; and Lopez, “Case for Prescription Heroin.”

119. Hari, Chasing the Scream; Weber, “Failure of Physicians,” pp. 171–73 (“Most addicts will simply stop, whether they are given treatment or not, provided prohibition doesn’t kill them first.”); and Richard Lawrence Miller, The Case for Legalizing Drugs (Westport, CT: Praeger Publishers, 1991), p. 53. (“Researchers have found chronological age to be a prevalent reason for drug use. Abuse is typically a young person’s habit, given up as the individual matures.”)

120. Nedelman, “Doctors Increasingly Face Charges.”

121. Malbran, “What’s a Pill Mill?”

122. CNN Wire Service, “10 People Died of Overdoses within 26 Hours in 1 Ohio County,”, WITI, September 30, 2019.

123. Lopez, “Case for Prescription Heroin”; and Bowers, “What If Nothing Works?”

124. H. Westley Clark and Karen Lea Sees, “Opioids, Chronic Pain, and the Law,” Journal of Pain and Symptom Management 8, no. 5 (July 1993): 297, 299.

125. Michigan Compiled Laws, Public Health Code Act 368 § 333.7333 (1978); Clark, “Opioids, Chronic Pain, and the Law,” p. 299; Szalavitz, “Most People with Addiction.” (“When a physician writes an opioid prescription, care must be taken to determine whether the person is an addict.”)

126. Susan Buckles, “4 Ways Individualized Medicine Can Be Applied Immediately to Patient Care,” Mayo Clinic News Network, October 5, 2016; and Lev Facher, “Tapered to Zero: In Radical Move, Oregon’s Medicaid Program Weighs Cutting Off Chronic Pain Patients from Opioids,” STAT News, August 15, 2018.

127. Art Levine, “The Government’s Solution to the Opioid Crisis Feels Like a War to Pain Patients,” HuffPost, July 31, 2018; and “U.S. Opioid Prescribing Rate Maps,” Centers for Disease Control and Prevention.

128. “U.S. Opioid Prescribing Rate Maps”; and Malbran, “What’s a Pill Mill?”

129. Levine, “Government’s Solution”; Terrence McCoy, “‘Unintended Consequences’: Inside the Fallout of America’s Crackdown on Opioids,” Washington Post, May 31, 2018; and Anson, “DEA Scrutiny.”

130. Levine, “Government’s Solution.” (“There’s evidence that thousands of prescription users cut off by fearful doctors are turning to dangerous street drugs, or being left to suffer.”)

131. Hari, Chasing the Scream, p. 226.

132. McCoy, “Unintended Consequences”; Murray Aitken and Michael Kleinrock, Medicine Use and Spending in the U.S.: A Review of 2017 and Outlook to 2022 (Durham, NC: IQVIA Institute, 2018) (opioid prescriptions shrank 29 percent between 2011 and 2017); Levine, “Government’s Solution”; Anson, “DEA Scrutiny”; Darius Tahir, “Databases Key to Trump’s Crackdown on Opioids,” Politico, June 29, 2018; and “Attorney General Sessions Announces New Prescription Interdiction and Litigation Task Force,” Department of Justice, news release, February 27, 2018.

133. Hari, Chasing the Scream; and Weber, “Failure of Physicians,” p. 231 (noting that, on the streets, Oxycontin is three times more expensive than heroin).

134. McCoy, “Unintended Consequences”; and Anson, “DEA Scrutiny.”

135. Levine, “Government’s Solution”; and McCoy, “Unintended Consequences” (internal quotations omitted).

136. “Sessions Announces,” U.S. Department of Justice.

137. “Sessions Announces,” U.S. Department of Justice.

138. Levine, “Government’s Solution”; and “Sessions Announces,” U.S. Department of Justice.

139. U.S. Department of Justice, “Attorney General Sessions Delivers Remarks Announcing National Health Care Fraud and Opioid Takedown,” news release, June 28, 2018.

140. Nedelman, “Doctors Increasingly Face Charges”; and Levine, “Government’s Solution.”

141. “Prescribing Opioids for Chronic Pain—United States, 2016,” Centers for Disease Control and Prevention, March 18, 2016.

142. Office of Arizona Governor Doug Ducey, Arizona Opioid Epidemic Act (2018), p. 13, (discusses limiting daily dosage levels to mirror CDC guidelines); Erika Ferrando, “New AR Medical Board Guidelines Limit Opioid Over-Prescribing,”, July 18, 2018 (discusses new Arkansas policy that sets “excessive” opioid prescription practices at just over half the daily CDC guideline); “Opioid Prescription Limits and Policies by State,”; Patty Wight, “Intent on Reversing Its Opioid Epidemic, a State Limits Prescriptions,” Morning Edition, NPR, August 23, 2017; Andy Marso, “Opioid Backlash: Kansas Citians in Chronic Pain Say Fewer Doctors Will Prescribe Meds,” Kansas City Star, September 2, 2018. By way of further example, the state of Missouri announced that it plans to crack down on 8,000 doctors for overprescribing opioids. See Marso, “Greitens Announces Opioid Crackdown That Could Affect 8,000 Missouri Doctors,” Kansas City Star, March 5, 2018. The number is astonishing, considering that there are only 19,000 physicians in the entire state; and “CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016.”

143. Lev Facher, “Tapered to Zero: In Radical Move, Oregon’s Medicaid Program Weighs Cutting Off Chronic Pain Patients from Opioids,” STAT News, August 15, 2018; “Sessions Announces,” U.S. Department of Justice; Marso, “Greitens”; Janet E. Joy, Stanley J. Watson Jr., and John A. Benson Jr., eds., Institute of Medicine, Marijuana and Medicine: Assessing the Science Base (Washington: National Academies Press, 1999), p. viii (describing Missouri HealthNet’s new rule requiring prescribers to adhere to CDC guidelines); McCoy, “Unintended Consequences”; and Pat Anson, “Dr. Forest Tennant Retiring Due to DEA Scrutiny,” Pain News Network, March 26, 2018.

144. Anson, “Dr. Forest Tennant Retiring.”

145. Anson, “Dr. Forest Tennant Retiring.”

146. Forest Tennant, “Ultra-High Dose Opioid Therapy: Uncommon and Declining, but Still Needed,” Practical Pain Management 13, no. 4 (May 2013).

147. Anson, “Dr. Forest Tennant Retiring.”

148. Brianna Ehley, “How the Opioid Crackdown Is Backfiring,” Politico, August 28, 2018; Levine, “Government’s Solution”; McCoy, “Unintended Consequences”; and Marso, “Opioid Backlash.” (“The result . . . has been a chilling effect nationally that has reduced the number of doctors willing to prescribe opioids and has left patients already dependent on them in the lurch.”)

149. Katie Fairbanks, “Opioid Regulations Worry Chronic Pain Patients, Doctors,” U.S. News & World Report, September 22, 2018.

150. Ehley, “How the Opioid Crackdown Is Backfiring”; and Erwin Chemerinsky, Jolene Forman, Allen Hopper, and Sam Kamin, “Cooperative Federalism and Marijuana Regulation,” UCLA Law Review 62, no. 1 (January 2015): 84–86.

151. Don C. Des Jarlais, “Harm Reduction in the USA: The Research Perspective and an Archive to David Purchase,” Harm Reduction Journal 14 (2017): 1, 3.

152. Scott Burris, David Finucane, Heather Gallagher, and Joseph Grace, “The Legal Strategies Used in Operating Syringe Exchange Programs in the United States,” American Journal of Public Health 86, no. 8 (1996): 1161.

153. Des Jarlais, “Harm Reduction in the USA,” p. 3; Jessie Balmert, “What Is Ohio Issue 1? Separating Fact from Fiction on Divisive Drug Ballot Initiative,”, November 5, 2018; and 42 U.S.C. § 300ee–5 (1988). (“None of the funds provided under this Act . . . shall be used to provide individuals with hypodermic needles or syringes so that such individuals may use illegal drugs.”)

154. Richard Weinmeyer, “Needle Exchange Programs’ Status in U.S. Politics,” American Medical Association Journal of Ethics 18, no. 3 (March 2016): 252, 253.

155. “History of Health: Needle Exchange in San Francisco,” San Francisco AIDS Foundation.

156. Des Jarlais, “Harm Reduction in the USA,” p. 4; and Balmert, “What Is Ohio Issue 1?”

157. Consolidated Appropriations Act, Pub. L. No. 114-113, § 520, 129 Stat. 2652 (2015); Weinmeyer, “Needle Exchange Programs’ Status in U.S. Politics”; and Shankar Vedantam, Jennifer Schmidt, Parth Shah, Tara Boyle, and Camila Vargas-Restrepo, “Life, Death, and the Lazarus Drug: Confronting America’s Opioid Crisis,” Hidden Brain podcast, NPR, June 24, 2019.

158. Marijuana Policy Project, “Medical Marijuana Map,”,

159. New Mexico Stat. Ann. § 26-2A-2 (West 1978); and Lester Grinspoon and James B. Bakalar, Marihuana: The Forbidden Medicine, rev. ed. (New Haven, CT: Yale University Press, 1997), pp. 4–7.

160. Joy, Marijuana and Medicine, p. viii; and Alex Kreit and Aaron Marcus, “Raich, Health Care, and the Commerce Clause,” William Mitchell Law Review 31, no. 3 (2005): 957, 959.

161. Conant v. Walters, 309 F.3d 629 (9th Cir. 2002).

162. 21 U.S.C. § 812(c)(10) (2018); Alliance for Cannabis Therapeutics v. Drug Enforcement Administration, 15 F.3d 1131, 1134–35 (D.C. Cir. 1994); Kreit, Controlled Substances: Crime, Regulation and Policy, p. 961; and Don Terry, “A Shot That Saves the Lives of Addicts Is Now in Their Hands,” New York Times, July 24, 2010.

163. Peter Grinspoon, “Medical Marijuana,” Harvard Health Publishing, Harvard Health Blog, January 15, 2018. The very narrow exception may be the Food and Drug Administration’s “Investigational New Drug” program, which permits studies on medical cannabis in narrowly circumscribed settings; and Robert C. Randall and Alice M. O’Leary, Marijuana Rx: The Patients’ Fight for Medicinal Pot (New York: Thunder’s Mouth Press, 1998), pp. 104–12.

164. Jordan Heller, “From Drug War to Dispensaries: An Oral History of Weed Legalization’s First Wave,”, Intelligencer, November 14, 2018.

165. Office of the Registrar of Voters, San Francisco Voter Information Pamphlet and Sample Ballot (San Francisco: Office of the Registrar of Voters, November 5, 1991), p. 12,; and “Santa Cruz County Measure A: Marijuana for Medical Use Initiative,” Schaffer Library of Drug Policy,

166. Chemerinsky, “Cooperative Federalism,” pp. 84–86; Compassionate Use Medical Marijuana Act, S.B. 119, 213th Leg., 2008 Sess. (N.J. 2009); Heller, “From Drug War to Dispensaries”; and Balmert, “What Is Ohio Issue 1?”

167. Bowers, “What If Nothing Works?”; Lopez, “Case for Prescription Heroin,” p. 784.

168. As both authors have examined elsewhere, court-imposed treatment depends upon a logical and normative flaw: the more typical drug-court graduate is the least compulsive user; the genuinely addicted drug user, by comparison, is likelier to fail out and face a draconian termination sentence—a jail or prison sentence longer, perhaps, than even traditional drug penalties. Daniel N. Abrahamson, “The Substance Abuse and Crime Prevention Act of 2000: The Parameters and Promise of Proposition 36,” California Criminal Defense Practice Reporter 2001, no. 11 (November 2001): 535, 536; Bowers, “What If Nothing Works?”; Lopez, “Case for Prescription Heroin,” pp. 789, 792–98 (“Studies found that the sentences for failing participants in New York City drug courts were typically two to five times longer than the sentences for conventionally adjudicated defendants.”); Daniel N. Abrahamson, “Drug Courts Are Not the Answer: Guest Commentary,” Los Angeles Daily News, May 12, 2015; and Drug Policy Alliance, Drug Courts Are Not the Answer: Toward a Health-Centered Approach to Drug Use (New York: Drug Policy Alliance, March 21, 2011).

169. In Debate of Legalizing Marijuana, Disagreement over Drug’s Dangers (Washington: Pew Research Center, April 14, 2015); and American Addiction Centers, “Voices from Both Sides of the Medical Marijuana Debate,”

170. Balmert, “What Is Ohio Issue 1?”

171. Jeannette Pforr, “Medication-Assisted Treatment: A Solution or Substitution,” IBH News (blog), IBH Solutions, February 6, 2018.

172. Michael C. Dorf and Charles F. Sabel, “Drug Treatment Courts and Emergent Experimentalist Government,” Vanderbilt Law Review 53, no. 3 (2000): 831, 841–43 (discussing development of first drug court in Miami Dade County, which was spearheaded by local officials who “actively sought more effective alternatives to incarceration”).

173. Corey S. Davis and Derek Carr, “Legal Changes to Increase Access to Naloxone for Opioid Overdose Reversal in the United States,” Drug and Alcohol Dependence 157 (December 2015): 112, 113 (noting that until 2015, “a patchwork of laws and legal considerations” blocked many people’s access to naloxone).

174. Vedantam, “Life, Death, and the Lazarus Drug”; and Daniel Kim, Kevin S. Irwin, and Kaveh Khoshnood, “Expanded Access to Naloxone: Options for Critical Response to the Epidemic of Opioid Overdose Mortality,” American Journal of Public Health 99, no. 3 (March 1, 2009): 402, 403.

175. “Public Policy Statement on the Use of Naloxone for the Prevention of Opioid Overdose Deaths,” American Society of Addiction Medicine, October 2016.

176. Leo Beletsky et al., “Physicians’ Knowledge of and Willingness to Prescribe Naloxone to Reverse Accidental Opiate Overdose: Challenges and Opportunities,” Journal of Urban Health 84, no. 1 (January 2007): 126, 130, 132; Jennifer L. Doleac and Anita Mukherjee, “The Moral Hazard of Lifesaving Innovations: Naloxone Access, Opioid Abuse, and Crime,” working paper, March 31, 2019; Kim, “Expanded Access to Naloxone”; Dorf, “Drug Treatment Courts”; and Heller, “From Drug War to Dispensaries” (discussing objections to expanded access).

177. Doleac, “Moral Hazard”; Burris, “Legal Strategies,” pp. 1, 36.

178. “Understanding Naloxone,” Harm Reduction Coalition,

179. John Keilman, “Dan Bigg Remembered as ‘Revolutionary’ for Approach to Heroin Crisis, Pioneered Life-Saving Naloxone, Needle Handouts,” Chicago Tribune, August 22, 2018.

180. Keilman, “Dan Bigg Remembered.”

181. Terry, “Shot That Saves the Lives of Addicts”; and Chris Bentley, “Chicago Recovery Alliance’s Naloxone Distribution Saves Lives,” Comer Family Foundation.

182. Corey Davis, Legal Interventions to Reduce Overdose Mortality: Naloxone Access and Good Samaritan Laws (Edina, MN: Network for Public Health Law, December 10, 2018).

183. Davis, Legal Interventions.

184. Linda Evans and Eve Goldberg, “‘Prisons Are Big Business’: The Prison-Industrial Complex and the Global Economy,” Centre for Research on Globalization, October 18, 2001.

185. Dorf, “Drug Treatment Courts”; Davis, Legal Interventions to Reduce Overdose Mortality, pp. 841–43; Heller, “From Drug War to Dispensaries”; Balmert, “What Is Ohio Issue 1?”; Kirchner; and Terry, “Shot That Saves the Lives of Addicts.”

186. Burris, “Legal Strategies”; and Grinspoon, The Forbidden Medicine, p. 1164 (discussing approaches taken by Philadelphia, Cleveland, Los Angeles, and San Francisco).

187. Grinspoon, The Forbidden Medicine, pp. 1162, 1164; Ricky N. Bluthenthal, Alex H. Kral, Jennifer Lorvick, and John K. Watters, “Impact of Law Enforcement on Syringe Exchange Programs: A Look at Oakland and San Francisco,” Medical Anthropology 18, no. 1 (1997): 61. On equitable discretion, see Bowers, “What If Nothing Works?”

188. “Lowest Law Enforcement Priority Jurisdictions,” Marijuana Policy Project; and Amanda Ross and Anne W. Walker, “The Impact of Low-Priority Laws on Criminal Activity: Evidence from California,” Contemporary Economic Policy 35, no. 2 (April 2017): 231, 241.

189. Ross, “Impact of Low-Priority Laws”; Jacewicz, Teaching Doctors About Addiction Medicine, p. 242, Table 1 and accompanying text; and Curtis VanderWaal, Jamie F. Chriqui, Rachel M. Bishop, and Duane McBride, “State Drug Policy Reform Movement: The Use of Ballot Initiatives and Legislation to Promote Diversion to Drug Treatment,” Journal of Drug Issues 36, no. 3 (2006): 619.

190. John Hudak and Grace Wallack, Ending the U.S. Government’s War on Medical Marijuana Research (Washington: Brookings Institution, October 20, 2015).

191. Alex Halperin, “Most in US Think Cannabis Has Health Benefits, Despite Lack of Data—Study,” The Guardian, July 23, 2018.

192. Janet Burns, “Opioid Activists Are Going Rogue to Prove That Safe Injection Sites Save Lives,” Forbes, August 10, 2017.

193. Burns, “Opioid Activists” (describing an unauthorized safe-injection site operating in the United States).

194. German Lopez, “Cities Are Considering Safe Injection Sites. A Federal Judge Just Said They’re Legal,” Vox, October 2, 2019.

195. Martha Bebinger, “AMA Endorses Trying Supervised Injection Facilities,” CommonHealth, WBUR, June 16, 2017.

196. Cherri Gregg, “Krasner: Philly DA’s Office Won’t Prosecute Those Using Safe Injection Sites,” CBS Philly, February 14, 2018; and Joyce Chen, “Philadelphia Wants to Be First U.S. City to Open Safe Injection Sites,” Rolling Stone, January 24, 2018 (quoting Philadelphia police commissioner Richard Ross, who is “keep[ing] an open mind” about supervised injection facilities).

197. Bobby Allyn, “As Philly Moves Closer to Supervised Injection Site, Gov. Wolf Remains Opposed,” WHYY, October 8, 2018.

198. Allyn, “As Philly Moves.”

199. Allyn, “As Philly Moves.”

200. United States v. Safehouse, Civil Action No. 19-0519 (E.D. Pa. October 2, 2019).

201. For instance, officials in Ithaca, New York, are likewise considering the reform. Lisa W. Foderaro, “Ithaca’s Anti-Heroin Plan: Open a Site to Shoot Heroin,” New York Times, March 22, 2016.

202. Elana Gordon, “What’s the Evidence That Supervised Drug Injection Sites Save Lives?,” NPR, September 7, 2018.

203. Natalie Jacewicz, “Teaching Doctors about Addiction Medicine,” Kaiser Health News, August 2, 2016.

204. Mental Health Parity and Addiction Equity Act, Pub. L. No. 110-343, 122 Stat. 3765 (2008) (modified by the Affordable Care Act to mandate coverage for addiction treatment and prohibit discrimination between addiction treatment and other essential health benefits).

205. Derrick A. Bell Jr., “Brown v. Board of Education and the Interest-Convergence Dilemma,” Harvard Law Review 93, no. 3 (January 1980): 518, 523; and Cockburn and St. Clair, Whiteout (describing “interest convergence” and white America).

206. Colby Itkowitz, “Senate Passes Sweeping Opioids Package,” Washington Post, September 17, 2018; and Office of Senator Michele Brooks, “Brooks’ Bill to Curb Suboxone Abuse Passes Senate,” press release, June 28, 2019.

207. Bell, “Brown v. Board of Education and the Interest-Convergence Dilemma,”; and Cockburn and St. Clair, Whiteout, and accompanying text.

208. Stephanos Bibas, The Machinery of Criminal Justice (Oxford: Oxford University Press, 2012).

209. “Good Samaritan Fatal Overdose Prevention Laws,” Drug Policy Alliance.

210. Matthew R. Jordan and Daphne Morrisonponce, “Naloxone,” National Center for Biotechnology Information, March 16, 2020,

211. Tibor M. Brunt et al., “Drug Testing in Europe: Monitoring Results of the Trans European Drug Information (TEDI) Project,” Drug Testing and Analysis 9, no. 2 (February 2017): 188–198 (presenting data on drug-testing systems in Spain, Switzerland, Belgium, Austria, Portugal, and the Netherlands).

212. Kate Sheridan, “How Effective Is Medication-Assisted Treatment for Addiction? Here’s the Science,” STAT News, May 15, 2017 (describing various studies on the effectiveness of medication-assisted treatment).

213. “Safe Injection Sites: Are They Helping or Hurting?,” Nova Recovery Center, November 14, 2018 (summarizing research on safe injection sites).

214. Evan MacDonald, “Heroin and Fentanyl Killed More People in Cuyahoga County in 2016 Than Homicides, Suicides and Car Crashes,”, May 24, 2017.